

Andrew S Allegretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2115478/publications.pdf>

Version: 2024-02-01

48
papers

1,259
citations

394421

19
h-index

377865

34
g-index

48
all docs

48
docs citations

48
times ranked

1854
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 16-25.	4.5	103
2	Shear wave elastography in chronic kidney disease: a pilot experience in native kidneys. BMC Nephrology, 2015, 16, 119.	1.8	96
3	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clinical Gastroenterology and Hepatology, 2022, 20, 1636-1662.e36.	4.4	95
4	Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group. American Journal of Kidney Diseases, 2019, 73, 372-384.	1.9	90
5	Blood Microbiome Profile in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 692-701.	4.5	84
6	Continuous renal replacement therapy outcomes in acute kidney injury and end-stage renal disease: a cohort study. Critical Care, 2013, 17, R109.	5.8	68
7	Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. International Journal of Nephrology, 2015, 2015, 1-9.	1.3	66
8	Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice. Journal of Clinical Investigation, 2020, 130, 3734-3749.	8.2	60
9	Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study. Clinical and Translational Gastroenterology, 2021, 12, e00359.	2.5	57
10	Clinical Application of Kidney Biomarkers in Cirrhosis. American Journal of Kidney Diseases, 2020, 76, 710-719.	1.9	55
11	Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. American Journal of Kidney Diseases, 2016, 68, 381-391.	1.9	45
12	Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. American Journal of Kidney Diseases, 2019, 74, 328-337.	1.9	43
13	Kidney Function Decline among Black Patients with Sickle Cell Trait and Sickle Cell Disease: An Observational Cohort Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 393-404.	6.1	35
14	Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. The Cochrane Library, 2017, 2017, CD005162.	2.8	32
15	Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Alimentary Pharmacology and Therapeutics, 2020, 52, 351-358.	3.7	30
16	Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology, 2019, 69, 729-741.	7.3	26
17	Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures. Clinical Gastroenterology and Hepatology, 2018, 16, 1832-1833.	4.4	23
18	Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement. PLoS ONE, 2019, 14, e0217442.	2.5	23

#	ARTICLE	IF	CITATIONS
19	Acute Kidney Injury Incidence, Recovery, and Long-term Kidney Outcomes Among Hospitalized Patients With COVID-19 and Influenza. <i>Kidney International Reports</i> , 2021, 6, 2565-2574.	0.8	22
20	Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. <i>American Journal of Kidney Diseases</i> , 2022, 79, 737-745.	1.9	22
21	Fluid assessment in dialysis patients by point-of-care magnetic relaxometry. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	20
22	Calciophylaxis: A Rare But Fatal Delayed Complication of Roux-en-Y Gastric Bypass Surgery. <i>American Journal of Kidney Diseases</i> , 2014, 64, 274-277.	1.9	19
23	Filter clotting with continuous renal replacement therapy in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 966-970.	2.1	19
24	Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance. <i>Liver International</i> , 2022, 42, 2124-2130.	3.9	18
25	The Gut and Blood Microbiome in IgA Nephropathy and Healthy Controls. <i>Kidney360</i> , 2021, 2, 1261-1274.	2.1	16
26	Accelerated Venovenous Hemofiltration as a Transitional Renal Replacement Therapy in the Intensive Care Unit. <i>American Journal of Nephrology</i> , 2020, 51, 318-326.	3.1	15
27	Chronic prolonged hyponatremia and risk of hip fracture in elderly patients with chronic kidney disease. <i>Bone</i> , 2019, 127, 556-562.	2.9	14
28	Acute Kidney Injury among Black Patients with Sick Cell Trait and Sick Cell Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 348-355.	4.5	10
29	Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3609-3620.	2.3	8
30	Renal Replacement Therapy for Acute Kidney Injury in Severe Alcohol-Associated Hepatitis as a Bridge to Transplant or Recovery. <i>Digestive Diseases and Sciences</i> , 2022, 67, 697-707.	2.3	7
31	The Effect of Bicarbonate Administration via Continuous Venovenous Hemofiltration on Acid-Base Parameters in Ventilated Patients. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	5
32	Perspectives of continuous renal replacement therapy in the intensive care unit: a paired survey study of patient, physician, and nurse views. <i>BMC Nephrology</i> , 2015, 16, 105.	1.8	5
33	Cardiovascular Outcomes in African Americans with Sick Cell Trait and Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2019, 49, 93-102.	3.1	5
34	Case 12-2017 "A 34-Year-Old Man with Nephropathy. <i>New England Journal of Medicine</i> , 2017, 376, 1575-1585.	27.0	4
35	Validity of International Classification of Diseases Codes for Sick Cell Trait and Sick Cell Disease. <i>Journal of General Internal Medicine</i> , 2020, 35, 1323-1324.	2.6	4
36	Acute Kidney Injury Following Paracentesis Among Inpatients With Cirrhosis. <i>Kidney International Reports</i> , 2020, 5, 1305-1308.	0.8	3

#	ARTICLE	IF	CITATIONS
37	The association between olfactory and gustatory dysfunction and chronic kidney disease. BMC Nephrology, 2022, 23, 36.	1.8	3
38	Acute Kidney Injury Treatment in Decompensated Cirrhosis: A Focus on Kidney Replacement Therapy. Kidney Medicine, 2021, 3, 12-14.	2.0	2
39	Small-diameter TIPS combined with splenic artery embolization in the management of refractory ascites in cirrhotic patients. Diagnostic and Interventional Radiology, 2021, 27, 232-237.	1.5	2
40	Bile Acids Are Important Contributors to AKI Associated with Liver Disease: CON. Kidney360, 2022, 3, 21-24.	2.1	2
41	Chronic disease, cancer, and exercise “a common link. Nature Reviews Nephrology, 2018, 14, 288-290.	9.6	1
42	Ferumoxitol-enhanced ultrashort TE MRA and quantitative morphometry of the human kidney vasculature. Abdominal Radiology, 2021, 46, 3288-3300.	2.1	1
43	Dialysis Filter Life in COVID-19: Early Lessons from the Pandemic. Kidney360, 2020, 1, 1334-1336.	2.1	1
44	Editorial: treating hepatorenal syndrome “a window and the views. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 897-897.	3.7	0
45	Letter: real-world use of terlipressin in patients with the hepatorenal syndrome “authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 350-351.	3.7	0
46	Response to Weng. Clinical and Translational Gastroenterology, 2021, 12, e00383.	2.5	0
47	Filter Clotting with Continuous Renal Replacement Therapy in COVID-19. Blood, 2020, 136, 22-23.	1.4	0
48	Letter: HRS “AKI “a frequent misdiagnosis in the real world setting? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1092-1092.	3.7	0